These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 33052224)

  • 1. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 2. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma.
    Deng G; Zeng F; He Y; Meng Y; Sun H; Su J; Zhao S; Cheng Y; Chen X; Yin M
    Clin Transl Med; 2022 Feb; 12(2):e722. PubMed ID: 35184394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
    Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
    J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.
    Wang Y; Su J; Wang Y; Fu D; Ideozu JE; Geng H; Cui Q; Wang C; Chen R; Yu Y; Niu Y; Yue D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):386. PubMed ID: 31481087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleosome assembly protein 1-like 4, a new therapeutic target for proliferation and invasion of melanoma cells.
    Mizuhashi S; Fukushima S; Ishibashi T; Kuriyama H; Kimura T; Kanemaru H; Kajihara I; Makino K; Miyashita A; Aoi J; Kita K; Ihn H
    J Dermatol Sci; 2021 Apr; 102(1):16-24. PubMed ID: 33583643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-22 targets FMNL2 to inhibit melanoma progression via the regulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
    Shi L; Huo JW; Chen SS; Xue JX; Gao WY; Li XY; Song YH; Xu HT; Zhu XW; Chen K
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5332-5342. PubMed ID: 31298385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-140-5p is negatively correlated with proliferation, invasion, and tumorigenesis in malignant melanoma by targeting SOX4 via the Wnt/β-catenin and NF-κB cascades.
    Zhao G; Yin Y; Zhao B
    J Cell Physiol; 2020 Mar; 235(3):2161-2170. PubMed ID: 31385607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.
    Giles KM; Brown RA; Ganda C; Podgorny MJ; Candy PA; Wintle LC; Richardson KL; Kalinowski FC; Stuart LM; Epis MR; Haass NK; Herlyn M; Leedman PJ
    Oncotarget; 2016 May; 7(22):31663-80. PubMed ID: 27203220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Karyopherin α 2 promotes proliferation, migration and invasion through activating NF-κB/p65 signaling pathways in melanoma cells.
    Yang F; Li S; Cheng Y; Li J; Han X
    Life Sci; 2020 Jul; 252():117611. PubMed ID: 32243925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.
    Ci C; Tang B; Lyu D; Liu W; Qiang D; Ji X; Qiu X; Chen L; Ding W
    Int J Mol Med; 2019 Jan; 43(1):404-412. PubMed ID: 30431060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.
    Wang X; Zhang F; Yang X; Xue M; Li X; Gao Y; Liu L
    Oncol Res; 2019 Aug; 27(8):871-877. PubMed ID: 30832751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway.
    Xu C; Sun L; Jiang C; Zhou H; Gu L; Liu Y; Xu Q
    Biomed Pharmacother; 2017 Jul; 91():1167-1177. PubMed ID: 28531945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.